PCSK9
From Proteopedia
(Difference between revisions)
(New page: <StructureSection load='2w2m' size='350' side='right' caption='Structure of human PCSK9 complex with LDL receptor EGF-A domain (PDB entry 2w2m)' scene=''> '''PCSK9''' or '''Propr...) |
|||
| Line 1: | Line 1: | ||
| - | + | <StructureSection load='2w2m' size='350' side='right' caption='Structure of human PCSK9 catalytic domain (grey) and prodomain (green) complex with LDL receptor EGF-A domain (magenta) and Ca+2 ion (PDB entry [[2w2m]])' scene=''> | |
| - | <StructureSection load='2w2m' size='350' side='right' caption='Structure of human PCSK9 complex with LDL receptor EGF-A domain (PDB entry [[2w2m]])' scene=''> | + | |
'''PCSK9''' or '''Proprotein Convertase Subtilisin/Kexin type 9''' is a proteinase which is an enzyme which is part of cholesterol synthesis. PCSK9 undergoes autocatalysis producing an active enzyme from its precursor. PCSK9 binds to EGF-A domain of the LDL receptor (LDLR) inducing its degradation. Low levels of LDL receptor are a cause of hypercholesterolemia since LDLR removes LDL cholesterol from the blood. Thus PCSK9 is an important drug target as its level affects the amount of cholesterol in blood. | '''PCSK9''' or '''Proprotein Convertase Subtilisin/Kexin type 9''' is a proteinase which is an enzyme which is part of cholesterol synthesis. PCSK9 undergoes autocatalysis producing an active enzyme from its precursor. PCSK9 binds to EGF-A domain of the LDL receptor (LDLR) inducing its degradation. Low levels of LDL receptor are a cause of hypercholesterolemia since LDLR removes LDL cholesterol from the blood. Thus PCSK9 is an important drug target as its level affects the amount of cholesterol in blood. | ||
Revision as of 10:10, 17 July 2013
| |||||||||||
